ANKTIVA approved for patients with certain indications of non-muscle invasive bladder cancer and non-small cell lung cancer -- Commercial availability achieved within two months of announcing MENA ...
Pfizer (NYSE:PFE) received U.S. FDA Priority Review for a supplemental Biologics License Application covering PADCEV plus ...
Merck, Pfizer and Astellas Pharma have won U.S. Food and Drug Administration priority review for their applications seeking expanded approval of their Keytruda/Padcev drug combination in certain ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...
Zacks Investment Research on MSN
MRK's SBLAs for Keytruda combo in bladder cancer get FDA priority tag
Merck MRK announced that the FDA has accepted the two supplemental biologics license applications (sBLAs) seeking approval ...
At the 2026 NCCN Annual Meeting, Dr. Charles Peyton spoke with CURE about how a growing number of treatment options is ...
As new therapies emerge, particularly for non-muscle invasive disease, clinicians and patients are faced with increasingly ...
A new study suggests that a urine-based biomarker test shows promise in forecasting bladder cancer treatment response, which ...
Pfizer (PFE) and Astellas (ALPMF) (ALPMY) announced Monday that the FDA has granted priority review for their marketing application, which seeks U.S. approval for their antibody drug conjugate, Padcev ...
Merck (MRK) stock climbed 3% after FDA granted priority review for KEYTRUDA bladder cancer treatment combination, with ...
Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...
Bladder cancer arises from the lining of the bladder, the organ that stores urine, and is one of the most common cancers in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results